(Q83166457)
Statements
The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands (English)
R Akehurst
N Brereton
R Ariely
T Lusa
M Groot
P Foss